What is SciTech Development?
SciTech Development operates as a clinical-stage specialty pharmaceutical entity dedicated to the advancement of oncology treatments. At the core of its innovation is the SciTech Drug Delivery Platform (SDP), a proprietary technology designed to overcome the persistent challenges of low bioavailability in traditional drug formulations. The company's flagship candidate, ST-001 nanoFenretinide, exemplifies this approach by integrating the SDP with fenretinide to optimize both safety and efficacy profiles. By focusing on these specialized delivery mechanisms, SciTech Development occupies a critical niche in the pharmaceutical sector, aiming to provide high-impact solutions for a variety of cancer indications that have historically proven difficult to treat with conventional methods.
How much funding has SciTech Development raised?
SciTech Development has raised a total of $8.2M across 2 funding rounds:
Other Financing Round
$2.7M
Debt
$5.5M
Other Financing Round (2023): $2.7M with participation from National Foundation for Cancer Research and Storm Lake Capital
Debt (2025): $5.5M, investors not publicly disclosed
Key Investors in SciTech Development
National Foundation for Cancer Research
The National Foundation for Cancer Research is a nonprofit organization dedicated to funding innovative cancer research aimed at finding cures for all types of cancer.
Storm Lake Capital
Storm Lake Capital is a value-based investment firm that partners with lower middle-market companies to enhance long-term value through flexible capital solutions and operational expertise.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for SciTech Development?
With the recent influx of capital, SciTech Development is poised to scale its clinical trial operations significantly. The strategic focus will likely center on the advancement of ST-001 through rigorous regulatory milestones, ensuring that the drug delivery platform achieves the necessary clinical data to support future commercialization efforts. Furthermore, the company is expected to leverage its current financial standing to forge additional strategic partnerships, which will be essential for navigating the complex landscape of late-stage drug development. As the firm transitions into this next phase of growth, the emphasis will remain on maintaining the integrity of its research while optimizing the scalability of its proprietary delivery technology to meet the urgent needs of the oncology market.
See full SciTech Development company page
